Plant Derived Lacto Ferrin Recombinant Human Lactoferrin rhLF With Endotoxin Less Than 20 EU / mg

Plant Derived Lacto Ferrin Human Recombinant Protein With Endotoxin Less Than 20 EU / mg​

Description

Wuhan Healthgen Biotechnology Corp. is based on the State-of-the-art platform called Oryz^HiExp. As a eukaryotic, rice has stable genetic characteristics. It can be ensured the recombinant lactoferrin bioactivity and stability in rice endosperm cells. It fundamentally ensures the high batches stability. The recombinant lactoferrin and native lactoferrin were treated in the different pH conditions, which result showed that the stability of Healthgen Biotech recombinant lactoferrin(OsrhLF) is equivalent to native LF. Healthgen Biotech plant platform can make sure the good batches consistency.

Quick detail

1. CAS No.: 146897-68-9
2. Other Names: Recombinan LTF, Plant-derived lactoferrin, recombinant lactoferrin, OsrhLF, rhLF, rLf, recombinant hLF, rec Lf
3. Place of Origin: Wuhan, China (Mainland)
4. Model Number: HYC004M01
5. Purity: Greater than 95 % as determined by SDS-PAGE
6. Physical Appearance: Russetish lyophilized powder
7. Formulation: OsrhLF is lyophilized with inorganic salt
8. Storage and Handling: Stored at temperatures 2-8℃ for 48 months

Advantages

1. The chairman of Healthgen Biotech Professor Daichang.Yang is one of China's chief scientists. Professor Yang has rechieved the “Thousand Talents program” of the National Central Organization Department, "Hundred Talents Program" of the Organization Department of Hubei Province and Top 10 "Venture Eagle" entrepreneurs.

2. With years of effort, Healthgen Biotech has developed the State-of-the-Art platform called Oryz^HiExp, having high capacity to express no animal origin proteins and peptides in the rice endosperm cells.

3. Healthgen Biotech recombinant human Lactoferrin(OsrhLF) is free of animal origin, which effectively avoid any potential risk of animal bacteria, prions, virus and contagious protein disease. 

Supplemental Description

Achievement and Honor

Healthgen Biotech obtained a number of patented technologies with independent intellectual property rights, including applied 9 national patents and 6 authorized patents, applied 7 international patents and 3 authorized patents. The international patents cover to United States, Japan, Europe and Canada. Moreover, two patents were authorized both by the Republic of South Africa and the United States. Based on rice endosperm specific expression technical platform-Oryz^HiExp, Healthgen Biotech, aim at the international forefront, takes the market as the orientation and enhances biotechnology innovation and engineering research, has won numerous awards.

Scientific Research Projects:

Major projects for New Drug Discovery, 3 projects of "Major projects of new varieties of genetically modified organisms” of the Ministry of Agriculture, National Ministry of Science and high Technology “863 plan”, National Ministry of Science and Technology Innovation fund, Pilot development of strategic emerging industries project

Talents Scheme:

“Thousand Talents program” of the National Central Organization Department, "Hundred Talents Program" of the Organization Department of Hubei Province, "3551 talents program” of the East Lake high-technology development zone , Top 10 "Venture Eagle" entrepreneurs.

Research Centers and Awards:

Wuhan National Biological Industry Base protein purification center, Hubei Molecular Biopharmaceutical Engineering Research Center, 2013 National Science and Technology Invention Award, 2012 Hubei Provincial Science and Technology Invention Award, 2013 China Patent Excellence Award, High-tech enterprise, Agricultural science and technology enterprise, Patent advantage enterprise.